A5092139238- SARS-CoV-2 and COVID-19 Research
- COVID-19 Clinical Research Studies
- Genetics and Neurodevelopmental Disorders
- Epigenetics and DNA Methylation
- Virus-based gene therapy research
- RNA modifications and cancer
- Complement system in diseases
- Viral Infections and Immunology Research
- Viral gastroenteritis research and epidemiology
Federal Medical-Biological Agency
2023
Anti-SARS-CoV-2 vaccination leads to the production of neutralizing as well non-neutralizing antibodies. In current study, we investigated temporal dynamics both sides immunity after with two doses Sputnik V against SARS-CoV-2 variants Wuhan-Hu-1 G614-variant (D614G), B.1.617.2 (Delta), and BA.1 (Omicron). First, constructed a pseudovirus assay assess neutralization activity vaccine sera. We show that serum compared D614G is decreased by 8.16-, 11.05-, 11.16- fold in 1, 4, 6 months...
INTRODUCTION. Developing novel medicines based on non-pathogenic enterovirus strains exhibiting oncotropic and oncolytic properties represents an up-to-date safe approach to complex cancer treatment postoperative metastasis prevention. Safety pharmacology studies are a necessary step in the preclinical development of medicinal products. AIM. The study aimed investigate single repeated-dose general toxicity, local tolerance, safety pharmacology, pyrogenicity products LEV4, LEV7, LEV8, LEV14,...